FGFR2 gene fusion is observed in approximately 14% of intrahepatic cholangiocarcinoma, which accounts for 15%-30% of all biliary tract cancers, according to Eisai, but drug options are limited.

The Bismuth–Corlette classification system provides an anatomic description ... They often manifest as a concentric thickening of the bile duct, coupled with infiltration of the periductal ...

Eisai has launched its new therapy for biliary tract cancer (BTC ... patients with this type of cancer – which is also known as cholangiocarcinoma. It was approved by the MHLW on the strength ...

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The ...

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is ...

Inebilizumab (Uplizna) treatment significantly reduced the risk of flares in patients who had IgG4-related disease (IgG4-RD) ...

To develop the combined model, the researchers integrated the imaging-derived radiomics score from the best-performing radiomics model (random forest) with the clinical model.

Non-invasive biomarkers and scoring systems show strong capability in differentiating chronic liver disease from cirrhosis, ...

CECT abdomen revealed a migrated cholecystectomy clip lodged in the common bile duct (CBD), leading to biliary obstruction. The patient was successfully treated with ERCP-guided clip removal, ...

Primary biliary cholangitis (formerly known as primary biliary cirrhosis ... In brief its key recommendations, based on the GRADE classification system (Strong/Weak; quality of evidence: High/Moderate ...

1 Department of Internal Medicine, Thai Nguyen University of Medicine and Pharmacy, Vietnam 2 Department of Internal Medicine, Thanh Ba Hospital, Vietnam 3 Department of Internal Medicine, 103 ...